Ademetionine
- Generic Name
- Ademetionine
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22N6O5S
- CAS Number
- 29908-03-0
- Unique Ingredient Identifier
- 7LP2MPO46S
- Background
Physiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms. It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed)
- Indication
S-Adenosylmethionine (SAMe) is used as a drug in Europe for the treatment of depression, liver disorders, fibromyalgia, and osteoarthritis. It has also been introduced into the United States market as a dietary supplement for the support of bone and joint health, as well as mood and emotional well being.
- Associated Conditions
- Fatigue, Intrahepatic Cholestasis, Major Depressive Disorder (MDD)
Reduced Nicotine Content Cigarettes in Smokers of Lower Socioeconomic Status
- Conditions
- Tobacco Dependence
- Interventions
- Drug: Reduced Nicotine Content Cigarettes
- First Posted Date
- 2013-08-27
- Last Posted Date
- 2019-05-01
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 280
- Registration Number
- NCT01928719
- Locations
- 🇺🇸
George Washington University School of Public Health, Washington, District of Columbia, United States
🇺🇸Penn State College of Medicine, Hershey, Pennsylvania, United States
Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)
- First Posted Date
- 2013-07-31
- Last Posted Date
- 2016-03-18
- Lead Sponsor
- MSI Methylation Sciences, Inc.
- Target Recruit Count
- 376
- Registration Number
- NCT01912196
- Locations
- 🇺🇸
MSI Investigational Site, Bellevue, Washington, United States
🇺🇸MSI INvestigational Site, Kissimmee, Florida, United States
Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group
- Conditions
- Non Alcoholic Fatty Liver Disease
- Interventions
- First Posted Date
- 2012-12-21
- Last Posted Date
- 2016-02-19
- Lead Sponsor
- Abbott
- Target Recruit Count
- 108
- Registration Number
- NCT01754714
- Locations
- 🇩🇪
Site Reference ID 93954, Frankfurt, Germany
🇫🇷Site Reference ID 93916, Nice, France
🇫🇷Site Reference ID 93895, Angers, France
A Trial of SAMe for Treatment-Resistant Bipolar Depression
- Conditions
- DepressionBipolar DisorderBipolar Depression
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Mclean Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT00762268
- Locations
- 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States
Effects of SAMe in Patients With Alcoholic Liver Disease
- Conditions
- Liver Disease, Alcoholic
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 94
- Registration Number
- NCT00573313
- Locations
- 🇺🇸
University of California, Davis Medical Center, Sacramento, California, United States
S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis
- Conditions
- Hepatitis
- First Posted Date
- 2005-04-18
- Last Posted Date
- 2009-01-21
- Lead Sponsor
- US Department of Veterans Affairs
- Registration Number
- NCT00108589
- Locations
- 🇺🇸
VA Medical Center, Louisville, Kentucky, United States
SAM-e for the Treatment of Depression in Patients With Parkinson's Disease
- Conditions
- Parkinson's DiseaseDepression
- Interventions
- First Posted Date
- 2003-10-13
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 29
- Registration Number
- NCT00070941
- Locations
- 🇺🇸
New York University, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.